Rogel Cancer Center: University of Michigan
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 115
- Registration Number
- NCT00603057
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
Phase 2
Terminated
- Conditions
- Cancer of Larynx
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00599131
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: INTENSITY MODULATED RADIOTHERAPY
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00593866
- Locations
- 🇺🇸
University Of Michigan, Ann Arbor, Michigan, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Phase 2
Completed
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00585689
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Radiation: IMRT
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00581529
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Radiation: 3DRadiation: IMRT
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00581256
- Locations
- 🇺🇸
University of Michigan Health Systems, Ann Arbor, Michigan, United States
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
Not Applicable
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT00580983
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Drug: PEG-IFN-a2b
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00573378
- Locations
- 🇺🇸
Universtiy of Michigan, Ann Arbor, Michigan, United States
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
Phase 2
Terminated
- Conditions
- Loco-regional Esophageal Cancer
- Interventions
- Radiation: Radiation TherapyProcedure: Esophagectomy
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00570531
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Phase 1
Terminated
- Conditions
- Bladder CancerNon-Small-Cell Lung CarcinomaProstate CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00565227
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath